证券代码：601607 证券简称：上海医药 编号：临 2025-112 上海医药集团股份有限公司 关于氨磺必利口崩片通过国家医保谈判并 成功纳入国家医保目录的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2025 年 12 月 7 日，国家医保局、人力资源社会保障部发布《国家基本医疗 保险、生育保险和工伤保险药品目录（2025 年）》（以下简称"《国家医保目 录》"），自 2026 年 1 月 1 日起执行。上海医药集团股份有限公司（以下简称 "公司"）下属上海上药中西制药有限公司（以下简称"上药中西"）的氨磺必 利口崩片（以下简称"该药品"） 通过国家医保谈判，成功纳入《国家医保目 录》。具体情况如下： 一、该药品基本情况 药品名称：氨磺必利口崩片 剂型：片剂 规格：50mg、0.2g 注册分类：化学药品 药品批准文号：国药准字 H20250041、国药准字 H20250042 协议有效期：自 2026 年 1 月 1 日至 2027 年 12 月 31 日 截至本公告日，中国境内氨磺必利口崩片暂无其他企业上市 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has successfully negotiated to include Amisulpride orally disintegrating tablets in the National Medical Insurance Directory, effective from January 1, 2026, to December 31, 2027 [1] Group 1 - Amisulpride orally disintegrating tablets are a modified formulation of Amisulpride tablets, which were launched by Sanofi in France in 1986, and are used for the treatment of adult schizophrenia [1] - As of the date of the announcement, there are no other companies in China that have listed Amisulpride orally disintegrating tablets [1] - According to the IQVIA database, the hospital procurement amount for Amisulpride oral formulations in 2024 is projected to be 168 million yuan [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced that its subsidiary, Shanghai Pharmaceuticals Zhongxi, has successfully negotiated for the inclusion of Amisulpride orally disintegrating tablets in the National Medical Insurance Directory [1] Group 1: Company Information - The Amisulpride orally disintegrating tablets are an improved formulation of the Amisulpride tablets launched by Sanofi in France in 1986 [1] - The drug is indicated for the treatment of adult schizophrenia [1] Group 2: Industry Impact - The inclusion of Amisulpride in the National Medical Insurance Directory may enhance its market accessibility and potentially increase sales [1]

Core Viewpoint - Shanghai Pharmaceuticals has officially terminated its cooperation agreement with Guizhou Shengnuo Biotechnology regarding the new acid suppressant project X842, based on a comprehensive assessment of the external market and overall business development plans of all parties involved [1][2]. Group 1: Termination Agreement Details - The termination agreement stipulates that Guizhou Shengnuo must return a total of 110 million yuan (approximately 15.5 million USD) in advance payment and development registration milestone fees to Shanghai Pharmaceuticals within 45 working days after signing the agreement [2]. - Guizhou Shengnuo is also required to pay a fund occupation fee at an annualized interest rate of 3% for the amount returned, calculated based on the actual days of fund occupation [2]. - The dispute resolution mechanism will follow the original agreement, applying Chinese law and submitting disputes to the China International Economic and Trade Arbitration Commission in Beijing [2]. Group 2: Market Context and Implications - The termination of the cooperation is seen as a result of significant changes in the market environment for the X842 project over the four years of collaboration, indicating that the competitive landscape for acid suppressants has become more intense [2]. - The market for proton pump inhibitors (PPIs) already has several established products, and the development progress and market acceptance of the new acid suppressants may not have met expectations [2]. - Shanghai Pharmaceuticals emphasized that the termination will not have a significant impact on its financial status or operational results, and it does not impose any additional unfavorable obligations on its subsidiary, Shanghai Shenyin [3].

Group 1 - The core point of the announcement is the termination of the cooperation agreement between Shanghai Pharmaceuticals and Guizhou Shengnuo Biotech, which was based on mutual agreement and does not impose additional obligations on Shanghai Pharmaceuticals [3][4]. - The original cooperation agreement was signed on October 8, 2021, granting Shanghai Pharmaceuticals exclusive rights for the production and industrial sales of the new acid suppressant X842 in China [2]. - The termination agreement stipulates that Shanghai Pharmaceuticals will receive a refund of 110 million yuan within 45 working days after the agreement is signed, along with interest at an annual rate of 3% [3]. Group 2 - Shanghai Pharmaceuticals' subsidiary, Shenyang Dongying, has received approval from the National Medical Products Administration for the production of Minoxidil solution, which is classified as a Class 3 chemical drug [7][8]. - The Minoxidil solution is available in two specifications: 2% and 5%, with the 2% formulation used for treating male pattern baldness and alopecia, while the 5% formulation is restricted to male use [9]. - The market for Minoxidil topical formulations in China was valued at approximately 236 million yuan in 2024, indicating a significant market opportunity for the newly approved product [10].

Group 1: Major Transactions - Bohai Chemical is planning to sell 100% equity of Tianjin Bohai Petrochemical and acquire control of Anhui Taida New Materials through a combination of share issuance and cash payment, leading to a significant asset restructuring [1] - Zhongneng Electric is set to acquire 65% equity and debt from three companies, which may constitute a major asset restructuring but will not involve share issuance or change in control [4] - Hai Tai Development has decided to terminate the acquisition of controlling interest in Zhixueyun Technology due to disagreements on key terms, ensuring no adverse impact on normal business operations [5] Group 2: Performance Updates - Wen's shares reported a sales revenue of 3.324 billion yuan from meat chickens in November, marking a year-on-year increase of 10.18% [6] - Shuguang shares saw a 71.07% year-on-year increase in vehicle sales, totaling 207 units in November [6] - Muyuan shares experienced a decline in sales revenue from commodity pigs, reporting 9.39 billion yuan, a decrease of 20.43% year-on-year [6] - Pengding Holdings reported a 5.58% year-on-year decrease in consolidated revenue for November [6] Group 3: Industry Developments - Xiangxi Dairy reported a 6.3% month-on-month increase in fresh milk production in November, although it saw a year-on-year decline of 6.47% [7] - Baisheng Intelligent plans to acquire 51% equity in Zhongke Shengu, which focuses on the research and application of core technologies for embodied intelligent robots [7]

Core Viewpoint - Shanghai Pharmaceuticals has terminated its cooperation agreement with Guizhou Shengnuo Biotech regarding the X842 project, leading to the return of a 110 million yuan upfront payment and associated fees [1][2]. Group 1: Agreement Details - On October 8, 2021, Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyu, signed a cooperation agreement with Guizhou Shengnuo for the production and sales of the new acid suppressant X842, granting exclusive rights in China, including Hong Kong, Macau, and Taiwan [1]. - The termination agreement was signed after a comprehensive market assessment and mutual discussions, with the original agreement remaining effective until the termination agreement takes effect [1]. Group 2: Financial Terms - The termination agreement stipulates that Guizhou Shengnuo must return the 110 million yuan upfront payment and development milestone fees to Shanghai Shiyu within 45 working days after the agreement takes effect, along with an annualized interest of 3% on the funds [2]. - On December 5, 2025, Shanghai Shiyu received the 110 million yuan payment, leading to the automatic termination of the original cooperation agreement, which no longer holds legal binding force [2].

北京商报讯（记者 丁宁）12月5日晚间，上海医药（601607）发布公告称，基于对外部市场的综合评 估，同时考虑各方整体经营发展规划，经友好协商，公司全资子公司上药信谊与贵州生诺、江苏生诺及 贵州生诺全资子公司上海生诺医药科技有限公司（三者合并简称"生诺生物"）签订了《生产、销售及开 发合作协议之终止协议》。 上海医药表示，本次与生诺生物终止对X842的合作不会对公司及上药信谊的财务状况及经营成果产生 重大影响，不存在损害公司及股东特别是中小股东利益的情形。 公告显示，2021年10月8日，上药信谊与贵州生诺及其全资子公司江苏生诺签署了新型抑酸剂X842 项目 （以下简称"X842"）的《生产、销售及开发合作协议》，上药信谊获得了X842原料药及制剂在中国区 域（包括香港、澳门及台湾）的独家委托生产和所有适应症的工业销售权。 ...

Core Viewpoint - Shanghai Pharmaceuticals has terminated its cooperation agreement with Guizhou Shengnuo Biotechnology regarding the new acid suppressant project X842, and has received a refund of 110 million yuan for the initial payment and development milestone fees [1][2]. Group 1: Termination of Cooperation - The termination agreement was signed on November 18, 2025, and the original cooperation agreement will automatically terminate after the refund is received [1]. - The company stated that this termination will not have a significant impact on its financial status or operating results [2]. Group 2: New Product Approval - On the same day, the company announced that its subsidiary, Jiangsu Dongying Pharmaceutical, received a drug registration certificate for Minoxidil lotion from the National Medical Products Administration [2]. - Minoxidil lotion is used for treating male pattern baldness and alopecia, with a market size of 2.361 billion yuan in China for 2024 [3]. - The approval is expected to enhance the market share and competitiveness of the product, while also providing valuable experience for future generic drug applications [3].

Group 1 - Shareholder of Xidiwei plans to reduce holdings by up to 3% of total shares, amounting to 12.37 million shares [2] - Minsheng Bank successfully issued 6 billion yuan of 3-year floating rate financial bonds to optimize its liability structure [3] - Baisheng Intelligent intends to acquire 51% stake in Zhongke Shengu for 100 million yuan, with a preliminary valuation of up to 200 million yuan [4] Group 2 - Junshi Biosciences received acceptance for the new drug application of Rocaqi monoclonal antibody injection for treating moderate to severe plaque psoriasis [5] - Ganneng Co. announced the successful commissioning of its clean coal power project, achieving national performance standards [6] - Yuekang Pharmaceutical plans to issue H-shares and list on the Hong Kong Stock Exchange [7][8] Group 3 - Qingtang City received notice of expropriation for Huaneng Mall, which will be shut down pending approval processes [9] - Meilixin's controlling shareholder plans to increase holdings by 50 million to 100 million yuan, with a maximum price of 52 yuan per share [10] - Zhenghong Technology reported a 20.43% year-on-year decline in November pig sales revenue [11][12] Group 4 - GAC Group reported a 9.72% year-on-year decline in November automobile sales, totaling 179,700 units [16] - Oupokangshi received approval for clinical trials of a new eye drop for treating presbyopia [17] - Kang En Bei announced the resignation of its chairman and legal representative due to work adjustments [18] Group 5 - Jiangxi Changyun is set to receive 15.7 million yuan in compensation for the expropriation of part of its properties [28] - Tianrun Dairy reported a 2.99% month-on-month increase in November pig sales revenue [29] - New Point Software won a 54 million yuan contract for a digital smart community construction project [31]